Literature DB >> 8106629

Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors.

Y Greenman1, S Melmed.   

Abstract

The expression of two somatostatin receptor subtypes, SSTR1 and SSTR2, was studied in 27 pituitary tumors and 1 chronic lymphocytic leukemia pituitary infiltrate. Solution hybridization techniques were used for RNA analysis. SSTR1 and SSTR2 were, respectively, expressed in 3 of 7 and 9 of 10 GH-secreting tumors, 1 of 9 and 5 of 9 nonfunctioning tumors, 4 of 5 and 0 of 5 of prolactinomas, and 1 of 3 and 0 of 3 ACTH-secreting tumors. The chronic lymphocytic leukemia infiltrate expressed the SSTR2 subtype. No correlation was detected among tumor size, level of hormonal hypersecretion, and somatostatin receptor expression status. Two acromegalic patients who responded to octreotide therapy exclusively expressed the SSTR2 subtype in their tumors. The results indicate that two SSTR subtypes are heterogeneously expressed in different pituitary adenoma cell types.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8106629     DOI: 10.1210/jcem.78.2.8106629

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  39 in total

Review 1.  The therapeutic value of somatostatin and its analogues.

Authors:  S Farooqi; J S Bevan; M C Sheppard; J A Wass
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

2.  SST3-selective potent peptidic somatostatin receptor antagonists.

Authors:  J C Reubi; J C Schaer; S Wenger; C Hoeger; J Erchegyi; B Waser; J Rivier
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.

Authors:  S Nielsen; S Mellemkjaer; L M Rasmussen; T Ledet; N Olsen; M Bojsen-Møller; J Astrup; J Weeke; J O Jørgensen
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

Review 4.  Somatostatin analogs as radiodiagnostic tools.

Authors:  Wouter W de Herder; Steven W J Lamberts
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

Review 5.  Pathogenesis of non-functioning pituitary adenomas.

Authors:  Maria Chiara Zatelli
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 6.  Somatostatin.

Authors:  T Reisine
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

7.  Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.

Authors:  I Shimon; J E Taylor; J Z Dong; R A Bitonte; S Kim; B Morgan; D H Coy; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 8.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

Review 9.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

10.  Ectopic ACTH syndrome caused by pheochromocytoma: computed tomography-guided percutaneous ethanol injection as an alternative treatment.

Authors:  D L Danilovic; R A Brandão Neto; H D'Abronzo; M R Menezes; A M Lucon; B B Mendonca
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.